December 1996
Volume 37, Issue 13
Free
Articles  |   December 1996
Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir.
Author Affiliations
  • Y J Gordon
    Department of Ophthalmology, Eye and Ear Institute, University of Pittsburgh Medical Center, Pennsylvania 15213, USA.
  • T P Araullo-Cruz
    Department of Ophthalmology, Eye and Ear Institute, University of Pittsburgh Medical Center, Pennsylvania 15213, USA.
  • Y F Johnson
    Department of Ophthalmology, Eye and Ear Institute, University of Pittsburgh Medical Center, Pennsylvania 15213, USA.
  • E G Romanowski
    Department of Ophthalmology, Eye and Ear Institute, University of Pittsburgh Medical Center, Pennsylvania 15213, USA.
  • P R Kinchington
    Department of Ophthalmology, Eye and Ear Institute, University of Pittsburgh Medical Center, Pennsylvania 15213, USA.
Investigative Ophthalmology & Visual Science December 1996, Vol.37, 2774-2778. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y J Gordon, T P Araullo-Cruz, Y F Johnson, E G Romanowski, P R Kinchington; Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir.. Invest. Ophthalmol. Vis. Sci. 1996;37(13):2774-2778.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

PURPOSE: Cidofovir (S-HPMPC) is a potent broad-spectrum antiviral drug with potential clinical application against infections caused by human cytomegalovirus, herpes simplex virus, and adenovirus (AD). This study sought to determine whether variants of AD5 could be isolated in vitro that demonstrated increased resistance to this new antiviral drug. METHODS: Homogenous stocks of wild-type AD5 (ATCC strain VR-5) were generated from isolated plaques grown in A549 cells. The stocks subsequently were serially passaged in cells containing increasing levels (from 5 to 75 micrograms/ml) of cidofovir. The recovered virus either was passaged, titrated, or assayed for 50% inhibitory concentration (IC50) of cidofovir. RESULTS: Three independently isolated variants were obtained that demonstrated increased resistance to cidofovir. Viral resistance to the drug increased on stepwise passage in higher concentrations. Compared to the ATCC AD5 reference (IC50 = 6.2 micrograms/ml), stable cidofovir-resistant variants showed fivefold to eightfold resistance (AD5 RI IC50 = 36.5 micrograms/ml; AD5 R2 IC50 = 36.7 micrograms/ml; and AD5 R3 IC50 = 32.6 micrograms/ml; analysis of variance, P = 0.000001). However, a variable number of passages (1 to 13) at each concentration of cidofovir was performed to obtain robust infectious virus suitable for testing at the next higher concentration. All resistant virus isolates grew to levels of virus titer comparable to the parental virus and showed no apparent phenotypic changes in growth rates, plaque size, or efficiency of plaque formation. CONCLUSIONS: The successful isolation of AD5 variants in tissue culture resistant to cidofovir has important clinical implications with respect to the anticipated use of this antiviral drug in treating adenoviral ocular infections.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×